Sun Pharma receives the green light from DCGI to market molnupiravir for the treatment of Covid-19


Sun Pharma announced Tuesday that its subsidiary has received Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of MSD and Ridgeback’s antiviral drug molnupiravir under the name Molxvir brand in India.

Earlier this year, the Mumbai-based pharmaceutical major signed a voluntary non-exclusive license agreement with MSD to manufacture and supply a generic version of molnupiravir in more than 100 low and middle-income countries (LMICs), including India.

The DCGI has approved molnupiravir for the treatment of adult patients with COVID-19 who are at high risk of disease progression, including hospitalization or death.

Molnupiravir is an important addition to the portfolio of oral therapies available for the treatment of patients with Covid-19, said Kirti Ganorkar, CEO of Sun Pharmaceutical Industries (India Business), in a statement.

“In line with our ongoing efforts to accelerate access to new drugs for the treatment of Covid-19, we will make Molxvir available to patients at an affordable price. We are also in the process of launching a free hotline to ensure availability of Molxvir. to doctors and patients across India. Our effort is to make the product available within a week, ”he added.

The recommended dose of the drug is 800 mg twice a day for five days.

The duration of treatment with molnupiravir is much shorter compared to other therapies, which is a significant advantage as it reduces pill load and improves adherence.

Molnupiravir was developed by MSD and Ridgeback Biotherapeutics.

It has been approved by the US Food and Drug Administration (FDA) and the UK Medicines and Health Products Regulatory Agency (MHRA) for Emergency Use Authorization (EUA).

(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor


Comments are closed.